Funded for PhII, biotech entrepreneurs achieve a 15-year-old R&D dream
Niels Riedemann and Renfeng Guo followed entirely different paths, but 15 years ago both wound up working together in the lab of Peter Ward at the University of Michigan, a prominent investigator known for his landmark research on the C5 pathway. That early teamwork created a bond over their insights into a particular avenue of the pathway that they hope will lead to a first-in-class anti-inflammatory drug. And they have now raised their first big chunk of cash — $34 million — to put it to its first big Phase II proof-of-concept challenge.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
